Symptoms of the disease include intense abdominal pain, bloating, constipation, or diarrhea. Often, patients also experience anxiety and depression. No biomarker has yet been identified for IBS, so no investigation can definitively say that somebody has IBS. Rather, the disease is usually diagnosed clinically.
Treatment options include medication and changes in diet, with a focus on eliminating so-called FODMAPS - a class of carbohydrates that are not easily assimilated by the gut and can cause fermentation in the bowels. The medication that is typically prescribed include antispasmodics and laxatives, but the efficacy of these therapies is limited, as the causes of IBS remain unknown.
A new study - carried out by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University in collaboration with researchers from the University of Waterloo, both in Ontario, Canada - may have found a link between gut bacteria in people with IBS and their behavioral symptoms. The findings, published in the journal Science Translational Medicine, may soon lead to new treatment options for those living with IBS.
The new research, led by Dr. Premysl Bercik and Dr. Stephen Collins, set out to investigate whether fecal microbiota from humans with IBS can alter the gut and brain function in mice.
Gut bacteria from human IBS patients transfers symptoms onto mice
For their study, the researchers used healthy, IBS-free individuals, as well as two groups of patients with IBS: one group that also had anxiety and another that did not. Using fecal transplants, they transferred the microbiota from these humans into germ-free mice.
After the transplant, the mice developed gastrointestinal and behavioral symptoms similar to those of their donors. The mice experienced gastrointestinal transit dysfunction (changes in the time it takes for food to travel from the stomach through the intestine), intestinal barrier dysfunction (in which the gastrointestinal tract does not provide a tight barrier against external, harmful bacteria as it normally would), inflammation, and behavior indicative of anxiety.
A research associate with the Farncombe Family Digestive Health Research Institute and the study's first author, Giada De Palma, explains the significance of the findings:
"This is a landmark study because it moves the field beyond a simple association, and towards evidence that changes in the microbiota impact both intestinal and behavioral responses in IBS."
Dr. Premysl Bercik, the study's lead author and associate professor of medicine at McMaster University, also weighs in:
"Our findings provide the basis for developing therapies aimed at the intestinal microbiota, and for finding biomarkers for the diagnosis of IBS," Bercik says.
The authors note that their findings may provide new opportunities for treatment development. "Microbiota-directed therapies, including pre- or probiotic treatment, may be beneficial in treating not only intestinal symptoms but also components of the behavioral manifestations of IBS," they conclude.
According to the authors, the results of their study also add to the mounting evidence that the gut's microbiota can affect the brain and a range of mental disorders. "The intestinal microbiota may play some role in the spectrum of brain disorders ranging from mood or anxiety to other problems that may include autism, Parkinson's disease, and multiple sclerosis," write Bercik and colleagues.
However, the authors concede that more studies are needed to fully clarify the connection between these conditions.